Message 1 of 1
Transdermal Topical Compounds Against Herpes, Herpes Zoster, Shingles, Psoriasis, Androgenic Alopecia (pattern baldness), and contact dermatitis. Pre-clinical research has demonstrated encouraging results in the delivery of the Company’s proprietary gene blocking DNA into cells via application directly to the skin using a simple and safe cream. This approach holds great promise for the treatment of several diseases. The Company is currently conducting laboratory research on blocking genes associated with Herpes, Herpes Zoster, Shingles, Psoriasis, Androgenic Alopecia (pattern baldness), and contact dermatitis. Initial animal studies, scheduled to commence in Mid-August will demonstrate the level of gene knockdown. Expanded studies on animal models for herpes and contact dermatitis will follow in the Fall. These studies will provide safety and efficacy data and required by the FDA for approval of an Investigational New Drug (IND). The Company plans to file for an IND and begin human trials in the 2nd or 3rd quarter of 2003. Building on the scientific foundation established in cell culture studies, CytoGenix (CYGX) will expand the proof of concept of its single stranded DNA expression technology in animals. The company is negotiating sponsored research agreements with two universities and a private laboratory to conduct experiments to test formulations to prevent or alleviate contact dermatitis and herpes. The anti-inflammatory formulation against contact dermatitis will have clinical applications to psoriasis, shingles and other dermatological conditions. Both sets of trials are scheduled to begin in August/September, 2002. The company expects to use the results of these animal studies to initiate a pre-Investigational New Drug (IND) conference with the Food and Drug Administration.